TOFANE-GLOBAL
9.1.2023 18:01:40 CET | Business Wire | Press release
Tofane Global (TOFANE), the leading international communications solutions group, announces today the acquisition of DIMOCO Messaging, a leading global SMS aggregator based in Liechtenstein and Austria that delivers around two billion messages per year.
Business messaging or application-to-person (A2P) has grown into a global market worth an estimated 26.5 billion USD in 2022 and is predicted to reach 38 billion USD in 2025. With only 5% of companies using SMS A2P, business adoption of messaging is still in its infancy but is starting to surge as organizations come to realize that business SMS can become a key revenue generator for mobile operators.**
With this acquisition, TOFANE’s subsidiary iBASIS significantly accelerates its growth, doubling mobile services revenues to reach 20% of the company’s total revenues.
The addition of DIMOCO Messaging enhances iBASIS’s carrier-grade network infrastructure by adding more than 100 direct connections to mobile operators worldwide, ensuring the highest standards of speed and reliability for message termination.
iBASIS geographically expands its global commercial presence with DIMOCO Messaging’s offices located in Liechtenstein, Austria, Germany, and Serbia.
The acquisition also gives direct access to the enterprise market segment where DIMOCO Messaging has an established sales force to serve large financial institutions, leveraging new SMS Application Program Interfaces for system integration, APIs for rapid onboarding, and SMS campaign deployment.
Alexandre Pébereau, CEO, iBASIS, and Founder, CEO, TOFANE:
“TOFANE established itself as the first independent leader through acquisitions in international voice. Today, we are replicating our model in the similar but high-growth Business Messaging sector to build our second pillar. By adding DIMOCO Messaging and its senior team, we are boosting our growth path to become the preferred Tier One partner for our customers in mobile services.”
Cameron Calof, Managing Director, DIMOCO Messaging:
“We are very excited to join iBASIS. The company has built a Tier One reputation as preferred partner for global voice and mobile services. We share the same entrepreneurial spirit, business ethics, and customer-centric approach, and are committed to delivering a high level of quality and reliability for messaging worldwide. We are thrilled for our employees and customers as this acquisition opens a new era of possibilities and growth. iBASIS’ expertise and capabilities are undisputed, and we look forward to continuing to respond to the industry’s fast-growing market requirements together.”
Jeantet acted as exclusive legal adviser, Mazars as finance and tax adviser, Wagram Corporate Finance as financial adviser, and Global Telco Consult – GTC as technical adviser on this acquisition.
* DACH: Deutschland (D), Austria (A), and Switzerland (CH)
** Mobilesquared, Business Messaging Overview at MEF Business Messaging, June 2022
About Tofane Global
Tofane Global (TOFANE) is the leading communications solutions group enabling operators and digital players worldwide with their core strategies, performance, and transformation. Tofane Global acquired and successfully integrated seven companies in the global communications market, becoming the first independent player and innovation enabler across international Voice, Mobile Data and SMS messaging, Internet-of-Things, and 5G. As the result of the acquisitions of Altice Europe N.V., iBASIS, SFR, MEO (former Portugal Telecom), NOS, and Simfony, Tofane Global serves 1,000+ customers worldwide across its presence in 26 countries.
About DIMOCO Messaging
Before its acquisition by Tofane Global, DIMOCO Messaging was owned by BaseTech Ventures, an investment venture that invests in early-stage FinTech, internet, and technology start-ups. DIMOCO Messaging provides high quality, reliable A2P messaging products enabling our enterprise clients to communicate to their customers on a truly global scale. We leverage our relationships with Mobile Network Operators, CPaaS and in-country partners to offer clients direct connectivity, allowing them to optimize communication with their customers and employees seamlessly. DIMOCO Messaging, with offices in Liechtenstein, Austria, Germany, and Serbia, holds an MVNO license and operates a carrier-grade messaging platform with highest quality industry standards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005012/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom